Clinical Trials Logo

Clinical Trial Summary

Diuretic therapy is first-line treatment for acute decompensated heart failure. However, accurate assessment and management of patient blood volume is challenged by the limitations of physical exam and surrogate markers for blood volume. The study primary objective is to determine if goal-directed care as quantified by direct Blood Volume Analysis (Daxor BVA-100™) in addition to usual care results in more appropriate treatment and consistent achievement of euvolemia.

Clinical Trial Description

Over 6 million Americans suffer from heart failure, one of the most prevalent and deadly diseases in the United States. High rates of rehospitalization and mortality and treatment costs have persisted for decades despite advances in care. Clinical guidelines recommend assessment of blood volume and clinical management to euvolemia or normal blood volume, but standard methods of diagnosing blood volume status have been shown to be unreliable. Blood Volume Analysis (Daxor BVA-100) is based on the gold standard indicator dilution technique. BVA has been used to quantify otherwise undiagnosed blood volume derangements and guide treatment in heart failure and other indications. Also, retrospective analyses have shown that care of heart failure patients guided by BVA is associated with improved rates of rehospitalization and mortality. The proposed study is a prospective, two-center, parallel design, interventional, single-blinded pilot study of the potential for BVA to positively impact the treatment decisions of ADHF clinicians. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04855097
Study type Interventional
Source Daxor Corporation
Contact Jonathan Feldschuh
Phone 9176091893
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date July 1, 2021
Completion date May 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04049045 - Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure Phase 2
Not yet recruiting NCT03951467 - Using an Intervention Adapted to the Health Literacy Level to Improve Adherence to Medical Recommendations N/A
Active, not recruiting NCT02898181 - Low Level Tragus Stimulation in Acute Decompensated Heart Failure N/A
Completed NCT02823626 - High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure
Completed NCT02248831 - Evaluation of Cardiopulmonary Diseases by Ultrasound N/A
Completed NCT02196038 - A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients N/A
Completed NCT00693745 - Neutrophil Gelatinase-Associated Lipcalin (NGAL) Evaluation Along With B-Type Natriuretic Peptide in Acutely Decompensated HF N/A
Not yet recruiting NCT04391231 - HEMolysis in a Percutaneous Axial Flow LVAD, Effects of Pentoxifylline in a Randomized Controlled Trial Phase 4
Recruiting NCT01960218 - Gas Exchange for Predicting Hospital Heart Failure Readmissions N/A
Terminated NCT00904488 - Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure Phase 4
Terminated NCT02620384 - Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study. Phase 3
Recruiting NCT04318093 - Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure Phase 2
Completed NCT02289508 - Role of USCOM in Adult Patients With Heart Failure N/A
Terminated NCT01457053 - Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics N/A
Recruiting NCT03505788 - Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR) Phase 4
Active, not recruiting NCT03146754 - A Study to Evaluate Lung Ultrasound as a Method to Measure Changes in Extravascular Lung Water Induced by Positional Changes (LUPE) N/A
Withdrawn NCT02721511 - A Study to Investigate the Safety and Efficacy of a Novel Furosemide Regimen Phase 1/Phase 2
Completed NCT01863511 - Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure Phase 4
Suspended NCT02440971 - Adaptive Servo Ventilation (ASV) in Heart Failure
Completed NCT00894387 - Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure Phase 3